

Evaluating the effectiveness of mRNA-1273.815 against COVID-19 hospitalization among adults aged ≥ 18 years in the United States

Amanda Wilson¹, Neloufar Rahai², Ekkehard Beck¹, Elisha Beebe², Brian Conroy², Daina Esposito¹, Priya Govil², Hagit Kopel¹, Tianyi Lu¹, James Mansi¹, Morgan A. Marks¹, Katherine E. Mues², Rohan Shah², Michelle Skornicki², Tianyu Sun¹, Astra Toyip², David Martin,^{1*} Andre B. Araujo¹

1. Moderna, Inc., Cambridge, MA, USA; *DM AND MAM contributed to this work while an employee of Moderna
2. Aetion, New York, NY, USA

Corresponding author: Amanda Wilson (Amanda.Wilson@modernatx.com),

SUPPLEMENTAL TABLES AND FIGURES

TABLES


Supplemental Table 1. Censoring Reasons

Censoring Reason	Exposed		Unexposed	
End of Data	1,240,802	97.53%	1,001,119	78.69%
2023/2024 Vaccine	7,231	0.57%	242,332	19.05%
Disenrollment	22,626	1.78%	26,128	2.05%
Outcome	1,502	0.12%	2,582	0.20%


Supplemental Table 2. Vaccine Effectiveness for Medically Attended COVID-19

Population	Number of Patients	Sum of Weights (Weighted Number of Patients)	Number of Events	Weighted Number of Events	Weighted Person-Time (years)	Incidence Rate per 100,000 PY (95% CI)	Exposed vs. Unexposed Vaccine Effectiveness* (95%CI)
Adults ≥18 Years							
Exposed	1,272,161	2,518,530	18,227	35,996	574,977	6,260.4 (6,195.9, 6,325.3)	25% (24%, 27%)
Unexposed	1,272,161	2,538,877	20,333	40,635	483,836	8,398.6 (8,317.2, 8,480.6)	
Adults 18-49 Years							
Exposed	445,343	880,966	4,980	9,907	197,122	5025.6 (4927.3, 5125.3)	28% (25%, 30%)
Unexposed	445,343	888,360	6,042	12,065	173,313	6961.7 (6838.3, 7086.7)	
Adults 50-64 Years							
Exposed	532,014	1,052,106	8,261	16,259	241,176	6741.53 (6638.31, 6845.55)	25% (23%, 27%)
Unexposed	532,014	1,061,611	9,146	18,395	202,500	9084.17 (8953.63, 9216.18)	
Adults ≥65 Years							
Exposed	294,388	583,095	5,028	9,934	135,955	7,306.8 (7,163.9, 7,451.2)	19% (16%, 22%)
Unexposed	294,388	588,125	4,881	9,612	107,640	8,929.8 (8,753.1, 9,110.1)	
High-Risk Adults ≥18 Years							
Exposed	766,178	1,518,158	13,039	25,563	346,387	7,379.8 (7,289.7, 7,470.6)	23% (21%, 24%)
Unexposed	766,178	1,528,811	14,085	28,419	290,907	9,769.0 (9,655.9, 9,883.0)	
Immunocompromised Adults ≥18 Years							
Exposed	236,490	468,650	4,583	8,998	108,280	8,310.3 (8,140.1, 8,483.5)	21% (18%, 24%)
Unexposed	236,490	472,291	4,685	9,430	87,994	10,716.2 (10,501.4, 10,933.9)	


FIGURES



Supplemental Figure 1. Distribution of Index Dates



Supplemental Figure 2. Log-log Kaplan-Meier curves for adults aged 18+



Supplemental Figure 3. Schoenfeld Residuals for adults aged 18+